SINGAPORE, Sept. 3, 2024 /PRNewswire/ -- Former Managing Director of a Geospatial Technology company, Board of Director and Chief Operating Officer at one of Singapore's top real estate firms, Simon Yio, is set to make a significant impact in the education sector. With nearly 20 years of experience in training and a proven track record of developing high-performance programmes for thousands of real estate professionals and leaders, Simon is now focusing on nurturing the next generation of leaders through education.
Simon, who is renowned for his dedication to creating and delivering effective training materials, is co-founding Mindsphere Singapore ("Mindsphere.sg") alongside Christine Chua. Christine, a Talent Development professional and adjunct lecturer, began teaching adolescents at the age of 17. "Simon and I recognize the transformative power of strong communication skills and are committed to bridging learning gaps through the skills-building programmes we designed," Christine said.
Mindsphere.sg, a premier training provider, is dedicated to developing exceptional communication skills among children, youths, and professionals. Their flagship offering, the Public Speaking Workshops, is designed for youths aged 11 to 16 and includes three progressive tiers—from beginner to advanced. Each tier features a carefully crafted curriculum that breaks down topics into manageable segments to ensure effective learning and practice.
In addition to his extensive experience in professional training, Simon has also served as a youth sports coach. His belief in the foundational values of sportsmanship informs his approach to education. Together with Christine, Simon developed the Learning Sphere and Curriculum Pyramid, which are central to their programmes.
Mindsphere.sg is also in talks with various organizations who are keen on developing their professionals at different stages of their careers. "With talent at the heart of our resilient economy, it is essential for individuals to be equipped with timeless skills," Simon emphasizes. "We take pride in our role in nurturing future leaders."
Mabel, an executive in the Banking and Finance sector and mother of three, adds, "Public speaking skills are crucial for children. They enhance communication and presentation abilities, boost confidence, and prepare them for future academic and professional opportunities."
As the founders of Mindsphere.sg put it, "In a world full of opportunities waiting to be unlocked, your soft skills are the keys."
Public Speaking Workshop (Beginner) for 11 to 16 year-olds will be held this November school holiday over 3.5 days at Orchid Country Club at a soft launch price. Reach out to the team via WhatsApp at +65 8180 4413 for more information.
About Mindsphere Singapore Pte Ltd
Mindsphere Singapore is a leading training provider driven by passion, a union of the founders' compassion, dedication and expertise in training and coaching. Mindsphere Singapore constantly seeks new methods and ideas to deliver effective teaching with workforce relevance in mind while upholding the highest standards of integrity and ethics. More than a learning hub, Mindsphere Singapore is a community committed to fostering growth, inspiring confidence, and nurturing the leaders of tomorrow.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Real Estate Veteran Leverages Two Decades of Training Expertise to Transform Education with Mindsphere Singapore
SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The results were published through poster presentation at the 2024 European Society for Medical Oncology (ESMO 2024).
This Phase I, open-label, dose-escalation and expansion study was conducted in China to assess the safety and efficacy of MVR-T3011 administered intravesically in patients with high-risk BCG-failure NMIBC. The study enrolled a broader patient population, including those with high-grade Ta, T1, or CIS +/- Ta/T1 bladder cancer, regardless of the presence of CIS. This inclusive approach aims to target a wider range of patients, potentially accelerating future trial enrollment and expanding market opportunities. The treatment was delivered via intravesical instillation at three dose levels, with weekly induction course lasting 12 weeks, followed by bi-weekly maintenance course for up to one year.
According to poster presented (cut-off as of June 27, 2024), among 14 evaluable patients, the overall 3-month complete response (CR) rate across all dose levels was 71.4% (10/14). At the 2×109 PFU dose level (expected RP2D), the CR rate reached an impressive 87.5% (7/8). The study showed a favorable safety profile, with no dose-limiting toxicities (DLTs) reported and no maximum tolerated dose (MTD) reached. Additionally, MVR-T3011 treatment simplifies clinical procedure by eliminating the need for bladder prewash by nature, further reducing patient discomfort. The instillation process is both quick and efficient.
By September 15, 2024, the most recent data shows that 20 subjects have received MVR-T3011 treatment. At the RP2D dose level, the 3-month CR rate remained strong at 81.8% (9/11). Of the 9 patients who have reached the 6-month assessment, 8 have maintained CR, while 4 patients have reached the 9-month assessment and all remained in CR. We are continuing to gather additional data to support further analysis.
"There is a significant unmet need for innovative treatments for bladder cancer," said Dr. Grace Zhou, Chairwoman and CEO of ImmVira. "We are highly encouraged by the preliminary safety and efficacy data from this Phase I study, especially the 3-month CR rate over 80%, along with durable responses at 6- and 9-month time points. With this early success, we are committed to accelerating clinical development of intravesical MVR-T3011 treatments for BCG-failure NMIBC patients and exploring its potential across other bladder cancer indications. Our goal is to provide a novel, effective, and well-tolerated treatment solution for patients."
About MVR-T3011
MVR-T3011, ImmVira's proprietary 3-in-1 oHSV, is a novel genetic engineered oHSV with advanced backbone design aiming to achieve the most favorable profile of attenuated HSV-1 with replication potency in tumor cells and highly restricted replication in normal cells, supporting intratumoral, intravenous and intravesical administrations. Additionally, MVR-T3011 incorporated two latest and well-validated exogenous genes, PD-1 antibody and IL-12, to further enhance immune responses in the tumor microenvironment.
About ImmVira
ImmVira is a biotechnology company focused on developing and synthesizing biological vector delivery platform. The company has constructed a fully integrated OVPENS® (Open Vector+ Potent, Enabling, Novel & Safe) platform with solid science, technology and CMC know-how, and three derivative subplatforms including Oncolytic Virus, Cancer Vaccine and Biosynthetic Exosome, to support ongoing R&D, clinical studies and commercialization of best-in-class mono and combo therapies driven by clinical benefits in oncology and non-oncology fields.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
